AGMB
AGMB
AgomAb Therapeutics N.V. American Depositary SharesIncome Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q4-2024 | $0 | $11.81M | $-11.73M | 0% | $0 | $-11.8M |
What's going well?
The company is investing heavily in research and development, which could pay off if it leads to future products or sales. Interest income helped reduce losses slightly.
What's concerning?
AGMB had zero revenue and a large net loss of $11.73 million. High spending with no sales is unsustainable unless the company can start generating revenue soon.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $129.59M ▼ | $165.63M ▼ | $18.7M ▲ | $146.93M ▼ |
| Q4-2024 | $171.46M | $206.36M | $18.28M | $188.08M |
What's financially strong about this company?
AGMB has a fortress-like balance sheet with $129.6 million in cash and almost no debt. They can easily cover all their bills and obligations, and have very little risk from hidden liabilities.
What are the financial risks or weaknesses?
Cash and equity both dropped sharply this quarter, suggesting the company is spending more than it brings in. Negative retained earnings show a history of losses, and if this trend continues, the cash cushion will shrink further.
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q4-2024 | $-11.73M | $-12.44M | $-363K | $81.86M | $68.86M | $-12.8M |
What's strong about this company's cash flow?
The company has a solid cash balance of $171.5 million after raising funds. It is not taking on new debt and has low capital spending.
What are the cash flow concerns?
AGMB is losing real cash from its core business and depends on selling new shares to survive. Shareholders are being diluted, and the business cannot sustain itself without more fundraising.
About AgomAb Therapeutics N.V. American Depositary Shares
https://agomab.comAgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases with a focus on chronic fibrotic indications with unmet medical needs.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q4-2024 | $0 | $11.81M | $-11.73M | 0% | $0 | $-11.8M |
What's going well?
The company is investing heavily in research and development, which could pay off if it leads to future products or sales. Interest income helped reduce losses slightly.
What's concerning?
AGMB had zero revenue and a large net loss of $11.73 million. High spending with no sales is unsustainable unless the company can start generating revenue soon.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $129.59M ▼ | $165.63M ▼ | $18.7M ▲ | $146.93M ▼ |
| Q4-2024 | $171.46M | $206.36M | $18.28M | $188.08M |
What's financially strong about this company?
AGMB has a fortress-like balance sheet with $129.6 million in cash and almost no debt. They can easily cover all their bills and obligations, and have very little risk from hidden liabilities.
What are the financial risks or weaknesses?
Cash and equity both dropped sharply this quarter, suggesting the company is spending more than it brings in. Negative retained earnings show a history of losses, and if this trend continues, the cash cushion will shrink further.
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q4-2024 | $-11.73M | $-12.44M | $-363K | $81.86M | $68.86M | $-12.8M |
What's strong about this company's cash flow?
The company has a solid cash balance of $171.5 million after raising funds. It is not taking on new debt and has low capital spending.
What are the cash flow concerns?
AGMB is losing real cash from its core business and depends on selling new shares to survive. Shareholders are being diluted, and the business cannot sustain itself without more fundraising.
CEO
Tim Knotnerus
Compensation Summary
(Year )
Ratings Snapshot
Rating : C-